KORU Medical Systems (NASDAQ:KRMD) Earns “Buy” Rating from Canaccord Genuity Group

KORU Medical Systems (NASDAQ:KRMD)‘s stock had its “buy” rating restated by investment analysts at Canaccord Genuity Group in a research note issued on Friday,Benzinga reports. They presently have a $6.00 target price on the stock. Canaccord Genuity Group’s price objective would indicate a potential upside of 40.19% from the company’s previous close.

Other equities research analysts have also recently issued reports about the stock. B. Riley Financial lifted their price target on shares of KORU Medical Systems from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Friday. Weiss Ratings reissued a “sell (d-)” rating on shares of KORU Medical Systems in a research report on Thursday, January 22nd. Craig Hallum restated a “buy” rating and issued a $7.00 target price on shares of KORU Medical Systems in a research note on Tuesday, January 13th. Lake Street Capital raised their target price on KORU Medical Systems from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Monday, December 22nd. Finally, Wall Street Zen raised KORU Medical Systems from a “buy” rating to a “strong-buy” rating in a research report on Monday, January 12th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $6.50.

KORU Medical Systems Stock Performance

Shares of KRMD stock opened at $4.28 on Friday. The company has a market cap of $198.26 million, a price-to-earnings ratio of -71.33 and a beta of 0.47. KORU Medical Systems has a 52 week low of $1.86 and a 52 week high of $6.61. The company has a quick ratio of 1.92, a current ratio of 2.48 and a debt-to-equity ratio of 0.01. The firm has a 50 day moving average of $5.10 and a 200-day moving average of $4.80.

KORU Medical Systems (NASDAQ:KRMD) last released its quarterly earnings data on Thursday, March 12th. The company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.01. KORU Medical Systems had a negative net margin of 6.41% and a negative return on equity of 16.04%. The company had revenue of $10.90 million during the quarter, compared to analyst estimates of $10.90 million. On average, equities analysts forecast that KORU Medical Systems will post -0.13 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Police & Firemen s Retirement System of New Jersey bought a new position in shares of KORU Medical Systems in the second quarter valued at $30,000. BNP Paribas Financial Markets increased its position in shares of KORU Medical Systems by 52.1% during the third quarter. BNP Paribas Financial Markets now owns 10,148 shares of the company’s stock worth $39,000 after acquiring an additional 3,478 shares in the last quarter. Lazard Asset Management LLC acquired a new stake in shares of KORU Medical Systems in the 2nd quarter worth about $59,000. Intech Investment Management LLC acquired a new stake in shares of KORU Medical Systems in the 2nd quarter worth about $73,000. Finally, Occudo Quantitative Strategies LP bought a new position in KORU Medical Systems in the 4th quarter valued at about $127,000. Institutional investors and hedge funds own 58.60% of the company’s stock.

Key Stories Impacting KORU Medical Systems

Here are the key news stories impacting KORU Medical Systems this week:

• Positive Sentiment: B. Riley raised its price target to $8.00 and maintained a “buy” rating, implying roughly an 87% upside from the current price — a meaningful vote of confidence from a major dealer. Benzinga
• Positive Sentiment: Canaccord Genuity reaffirmed its “buy” rating and set a $6.00 target (≈40% upside), adding further analyst support for upside to the stock. Benzinga
• Positive Sentiment: KORU received EU MDR certification for its Freedom60® infusion pump with prefilled syringe compatibility — clear regulatory progress that should aid European commercialization and recurring revenue potential. Las Vegas Sun
• Positive Sentiment: Q4 2025 results beat EPS expectations (loss of $0.01 vs. -$0.02 est.), reported ~20% revenue growth and positive adjusted EBITDA; management also initiated FY2026 guidance with revenue of $47.5M–$50.0M (roughly in line with consensus ~ $48.8M). These operational improvements support medium-term growth prospects. Business Wire – Q4 & Guidance
• Neutral Sentiment: Analysts and the company provided forward revenue guidance but EPS guidance detail was not clearly disclosed in public summaries; revenue range is encouraging but leaves some near-term visibility questions. Q4 Press Release / Slide Deck
• Negative Sentiment: KORU announced a CEO transition: long-time CEO Linda Tharby will retire June 30 and the board appointed Adam Kalberma as successor. Leadership changes introduce short-term execution risk and can pressure the stock until the market judges the new CEO. Business Wire – CEO Transition
• Negative Sentiment: Despite positives, KRMD still shows a negative net margin and negative ROE; valuation and profitability concerns may keep selling pressure, which likely explains why the stock is trading lower even after upgrades and regulatory wins.

KORU Medical Systems Company Profile

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.